Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

STARCOIN GROUP LIMITED
星太鏈集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

QUARTERLY UPDATES ON PROGRESS OF RESUMPTION AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Starcoin Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) ("**SFO**").

References are made to (i) the announcements of the Company dated 5 May 2026 and 1 June 2026 in relation to, among other things, the results of the application for judicial review of the Listing Review Committee's decision and the interim injunction sought, and the guidance for resumption of trading issued by the Stock Exchange to the Company; (ii) the announcements of the Company dated 30 June 2026 in relation to, among other things, the delay in publication of the audited annual results of the Group for the year ended 31 March 2026 (the "**2026 Annual Results**") and the delay in despatch of the 2026 annual report; (iii) the announcement of the Company dated 5 August 2026 in relation to the first quarterly update on progress of resumption; and (iv) the announcement of the Company dated 17 August 2026 in relation to the additional guidance for resumption of trading issued by the Stock Exchange to the Company (the "**Additional Resumption Guidance**") (collectively, the "**Announcements**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

UPDATE ON BUSINESS OPERATIONS

The Company is an investment holding company. The Group is principally engaged in the trading of beauty and healthcare products and the research and development of oral insulin. Since the suspension of trading in the shares of the Company (the "**Shares**") on 6 May 2026 and up to the date of this announcement, the Group has continued its business operations in all material respects.

RESUMPTION GUIDANCE

On 28 May 2026, the Company received a letter from the Stock Exchange setting out the following guidance (the "**Resumption Guidance**") for the resumption of trading in the Shares:

(i) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules; and

(ii) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

On 12 August 2026, the Company received a further letter from the Stock Exchange setting out the Additional Resumption Guidance, requiring the Company to (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications; and (ii) engage an independent internal control consultant to conduct an independent internal control review and demonstrate the adequacy and effectiveness of the Company's internal controls. For details, please refer to the announcement of the Company dated 17 August 2026.

UPDATE ON RESUMPTION PLAN

The Company has been assessing the implications of Rule 13.24 of the Listing Rules. As disclosed in the announcement of the Company dated 5 August 2026, the Company has engaged Donvex Capital Limited as its financial adviser to assist with the resumption process and to formulate the necessary measures required for compliance with the Listing Rules. The Company has continued to actively seek acquisition and cooperation opportunities and to explore ways to optimise its trading of beauty and healthcare products, while expanding and diversifying its related businesses, with the aim of developing a comprehensive and feasible resumption plan that addresses all matters set out in the Resumption Guidance and the Additional Resumption Guidance.

As disclosed in the announcement of the Company dated 30 June 2026, the publication of the 2026 Annual Results has been delayed as the Company is required to provide further information to the auditor of the Company, including but not limited to the impairment assessment of intangible assets and the going concern assessment. The Company has been working closely with the auditor to provide all required information and maintain active communication, with a view to resolving all outstanding matters and completing the audit of the 2026 Annual Results as soon as practicable. The expected date of publication of the 2026 Annual Results is subject to further discussion with the auditor and will be announced as and when appropriate.

As at the date of this announcement, the Company is in the process of identifying a suitable independent internal control consultant to conduct the independent internal control review as required under the Additional Resumption Guidance. Further announcement(s) will be made by the Company as and when appropriate.

The Company will publish further announcement(s) as and when appropriate and in accordance with the requirements of the Listing Rules to keep its shareholders and potential investors informed of the latest progress of the Company in complying with the Resumption Guidance and the Additional Resumption Guidance.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 6 May 2026, and will remain suspended until further notice.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 5 November 2026

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: starcoingroup.com.